urothelial
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 people.
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrea Necchi Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University · IRCCS Ospedale San Raffaele Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies. | Bladder & urothelial cancer | none | neoadjuvant, italy | ||
Arjun V. Balar Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer. | Bladder & urothelial cancer | none | immunotherapy | ||
Ashish M. Kamat Professor of Urology and Cancer Biology, MD Anderson Cancer Center · MD Anderson Cancer Center Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group. | Bladder & urothelial cancer | none | surgery, bcg | ||
Dean F. Bajorin Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery. | Bladder & urothelial cancer | none | adjuvant, immunotherapy | ||
Joaquim Bellmunt Director, Bladder Cancer Center, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School · Dana-Farber Brigham Cancer Center Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer. | Bladder & urothelial cancer | none | immunotherapy | ||
Jonathan E. Rosenberg Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer. | Bladder & urothelial cancer | none | adc, immunotherapy | ||
Stephen A. Boorjian Chair of Urology, Mayo Clinic · Mayo Clinic Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG. | Non-muscle-invasive bladder cancer, Bladder & urothelial cancer | none | gene-therapy, surgery, trialist | ||
Thomas Powles Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London · Barts Cancer Institute / Barts Health NHS Trust Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care. | Bladder & urothelial cancer, Renal cell carcinoma | none | adc, ctdna, trialist |
